在OGTT期间异黄素,氨酸和二甲基甘氨酸的变化作为糖尿病风险因素
Yixian Liu1, Xiaoxuan Liu1, Qian He1
1Department of Clinical Laboratory, Tianjin Medical University General Hospital, Heping District, Tianjin 300052, China.
The Journal of clinical endocrinology and metabolism
|January 12, 2024
概括
经过口服葡萄糖耐受性测试后的代谢学分析显示,不同葡萄糖耐受性的个体具有不同的代谢特征. 在测试期间发生的特定代谢物变化是糖尿病风险的潜在指标.
科学领域:
- 代谢学 代谢学 代谢学
- 糖尿病研究 糖尿病研究
- 葡萄糖的新陈代谢
背景情况:
- 有限的代谢学研究集中在糖尿病的禁食状态上.
- 很少有研究研究了和状态中的代谢变化.
研究的目的:
- 结合口服葡萄糖耐受性测试 (OGTT) 和代谢学来分析代谢物变化.
- 评估这些变化作为糖尿病风险因素的潜力.
主要方法:
- 参与者被分为正常的葡萄糖耐受性 (NGT),受损的葡萄糖调节 (IGR) 和新诊断的2型糖尿病 (NDM) 组.
- 在OGTT期间,血清样本在多个时间点收集.
- 使用通用估计方程 (GEE) 分析来评估代谢物水平与糖尿病风险之间的关系.
主要成果:
- 摄入葡萄糖改变了代谢特征,增加了糖溶性中间体,减少了氨基酸,糖醇,体和甘油三.
- 在NGT和糖尿病/IGR组之间,异黄素水平有显著差异.
- 在OGTT期间的异黄素,素和酸水平与新诊断的糖尿病和葡萄糖调节受损的风险有关.
结论:
- 在具有不同葡萄糖耐受性状态的个体中,新陈代谢资料在葡萄糖挑战后呈现出不同的模式.
- 在OGTT期间观察到的代谢物水平变化是糖尿病发展的潜在风险因素.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
176
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
176
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Diabetes: Symptoms, Diagnosis, and Complications
546
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
546
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325


